The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing

Authors

Sarah Adler, Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET)
Gerd Bicker, University of Veterinary Medicine Hannover
Hans Bigalke, Hannover Medical School
Christopher Bishop, Wickham Laboratories
Jörg Blümel, Merz Pharmaceuticals
Dirk Dressler, Rostock University
Joan Fitzgerald, Allergan, Inc.
Frank Gessler, University of Göttingen
Heide Heuschen, Federal Institute for Drugs and Medical Devices (BfArM)
Birgit Kegel, Paul-Ehrlich-Institut
Andreas Luch, Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET)
Catherine Milne, European Directorate of the Quality of Medicines and Health Care
Andrew Pickett, Ipsen Biopharm Limited
Heidemarie Ratsch, Landesamt für Gesundheit und Soziales Berlin
Irmela Ruhdel, Akademie für Tierschutz
Dorothea Sesardic, National Institute for Biological Standards and Control
Martin Stephens, The Humane Society of the United StatesFollow
Gerhard Stiens, Federal Ministry of Food, Agriculture and Consumer Protection (BMELV)
Peter D. Thornton, Animals Scientific Procedures Inspectorate
René Thürmer, Federal Institute for Drugs and Medical Devices (BfArM)
Martin Vey, Merz Pharmaceuticals
Horst Spielmann, Free University of BerlinFollow
Barbara Grune, Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET)
Manfred Liebsch, Centre for Documentation and Evaluation of Alternatives to Animal Experiments (ZEBET)

Document Type

Article

Publication Date

2010

Recommended Citation

Adler, S., Bicker, G., Bigalke, H., Bishop, C., Blümel, J., Dressler, D., ... & Liebsch, M. (2010, August). The current scientific and legal status of alternative methods to the LD50 test for botulinum neurotoxin potency testing. In The report and recommendations of a ZEBET Expert Meeting. ATLA (Vol. 38, No. 4, pp. 315-330).